Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:OCUL
- CUSIP: N/A
- Web: www.ocutx.com
Capitalization:- Market Cap: $168.52 million
- Outstanding Shares: 29,056,000
Average Prices:- 50 Day Moving Avg: $6.67
- 200 Day Moving Avg: $8.60
- 52 Week Range: $4.82 - $11.91
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.71
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $1.9 million
- Price / Sales: 88.70
- Book Value: $1.65 per share
- Price / Book: 3.52
Profitability:- EBIDTA: ($54,640,000.00)
- Net Margins: -3,005.52%
- Return on Equity: -101.03%
- Return on Assets: -69.76%
Debt:- Debt-to-Equity Ratio: 0.32%
- Current Ratio: 5.20%
- Quick Ratio: 5.20%
Misc:- Average Volume: 1.25 million shs.
- Beta: 1.59
- Short Ratio: 3.03
Frequently Asked Questions for Ocular Therapeutix (NASDAQ:OCUL)
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.05. The firm earned $0.40 million during the quarter, compared to the consensus estimate of $0.51 million. Ocular Therapeutix had a negative net margin of 3,005.52% and a negative return on equity of 101.03%. The business's revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. View Ocular Therapeutix's Earnings History.
When will Ocular Therapeutix make its next earnings announcement?
Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2017?
6 brokerages have issued 1 year target prices for Ocular Therapeutix's stock. Their predictions range from $8.00 to $60.00. On average, they expect Ocular Therapeutix's share price to reach $24.00 in the next twelve months. View Analyst Ratings for Ocular Therapeutix.
What are analysts saying about Ocular Therapeutix stock?
Here are some recent quotes from research analysts about Ocular Therapeutix stock:
- 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/23/2017)
- 2. Cantor Fitzgerald analysts commented, "We are initiating on Ocular Therapeutix with an Overweight rating and $35 Price target. We believe Ocular's portfolio of sustained release therapies have the potential to treat an array of ophthalmic conditions with significant unmet need. In focus, we view the upcoming FDA decision this year for lead developmental candidate DEXTENZA' in post-surgical ocular pain as a meaningful catalyst for the shares, and estimate that DEXTENZA could reach annual sales of $600 million at peak market penetration in 2023, with further growth to $900 million by 2030 for this indication alone in the U.S." (2/9/2017)
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include Utah Medical Products (UTMD), Sientra (SIEN), SeaSpine Holdings Corporation (SPNE), T2 Biosystems (TTOO), Transenterix (TRXC), Transenterix (TRXC), Bioquell plc (BQE), Tandem Diabetes Care (TNDM), Surgical Innovations Group Plc (SUN), Capnia (SLNO), Alliqua BioMedical (ALQA), Lombard Medical (EVAR), Cytori Therapeutics (CYTX), NeuroMetrix (NURO), InspireMD (NSPR), CareFusion (CFN), Covidien Ltd (COV) and CRH Medical Corp (CRHM).
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the folowing people:
- Amarpreet Sawhney Ph.D., Executive Chairman of the Board
- James Fortune, Interim Principal Financial Officer, Chief Operating Officer, Interim Princiapl Accounting Officer
- George V. Migausky, Interim Chief Financial Officer
- Eric P. Ankerud, Executive Vice President, Regulatory, Quality and Compliance
- Andy Hurley, Chief Commercial Officer
- Jonathan Talamo M.D., Chief Medical Officer
- Jaswinder S. Chadha, Director
- W. James O'Shea, Director
- Jeffrey S. Heier M.D., Independent Director
- Richard L. Lindstrom M.D., Independent Director
Who owns Ocular Therapeutix stock?
Ocular Therapeutix's stock is owned by many different of retail and institutional investors. Top institutional investors include Versant Venture Management LLC (7.63%), Jennison Associates LLC (6.84%), SV Health Investors LLC (5.53%), FMR LLC (4.56%), Vanguard Group Inc. (3.12%) and Columbus Circle Investors (1.99%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney and James Fortune. View Institutional Ownership Trends for Ocular Therapeutix.
Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?
Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Columbus Circle Investors, Deltec Asset Management LLC, FMR LLC, JPMorgan Chase & Co., Edmond DE Rothschild Holding S.A., Wells Fargo & Company MN and NEXT Financial Group Inc. View Insider Buying and Selling for Ocular Therapeutix.
Who bought Ocular Therapeutix stock? Who is buying Ocular Therapeutix stock?
Ocular Therapeutix's stock was purchased by a variety of institutional investors in the last quarter, including Cowen Inc., State Street Corp, Northern Trust Corp, Parametric Portfolio Associates LLC, Neuberger Berman Group LLC, State of Wisconsin Investment Board, Alliancebernstein L.P. and Voya Investment Management LLC. View Insider Buying and Selling for Ocular Therapeutix.
How do I buy Ocular Therapeutix stock?
Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocular Therapeutix's stock price today?
One share of Ocular Therapeutix stock can currently be purchased for approximately $5.80.
MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $24.00 (313.79% upside) |
Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/10/2017 | BTIG Research | Reiterated Rating | Neutral | | Low |  |
| 8/9/2017 | HC Wainwright | Reiterated Rating | Buy | $10.00 | High | |
| 7/14/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $16.00 -> $8.00 | Low | |
| 7/12/2017 | Cantor Fitzgerald | Lower Price Target | Overweight -> Overweight | $35.00 -> $21.00 | High | |
| 3/13/2017 | Cowen and Company | Reiterated Rating | Outperform | $60.00 | Medium | |
| 11/15/2016 | Royal Bank Of Canada | Reiterated Rating | Outperform | $30.00 -> $32.00 | N/A | |
| 8/11/2016 | JMP Securities | Initiated Coverage | Outperform | $21.00 -> $5.84 | N/A | |
(Data available from 8/21/2015 forward)
Earnings History for Ocular Therapeutix (NASDAQ:OCUL)Earnings History by Quarter for Ocular Therapeutix (NASDAQ OCUL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.54) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.59) | ($0.64) | $0.51 million | $0.40 million | View | Listen | |
| 5/5/2017 | Q1 2017 | ($0.48) | ($0.58) | $0.51 million | $0.48 million | View | N/A | |
| 3/10/2017 | Q4 2016 | ($0.45) | ($0.52) | $0.48 million | $0.51 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.50) | ($0.39) | $0.47 million | $0.48 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.49) | ($0.46) | $0.55 million | $0.44 million | View | Listen | |
| 5/10/2016 | Q116 | ($0.43) | ($0.44) | | $458.00 million | View | Listen | |
| 3/10/2016 | Q415 | ($0.47) | ($0.43) | | $0.44 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.38) | ($0.47) | | $0.43 million | View | Listen | |
| 8/10/2015 | Q215 | ($0.33) | ($0.45) | | $0.46 million | View | Listen | |
| 5/15/2015 | Q115 | ($0.39) | ($0.35) | $0.30 million | $0.43 million | View | Listen | |
| 3/10/2015 | Q4 | ($0.38) | ($0.37) | $0.20 million | $0.51 million | View | Listen | |
| 11/12/2014 | Q3 14 | ($0.55) | ($0.48) | $0.10 million | $0.14 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)Current Year EPS Consensus Estimate: $-2.28 EPS
Next Year EPS Consensus Estimate: $-2.14 EPS
Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ocular Therapeutix (NASDAQ:OCUL)Insider Ownership Percentage: 26.10%
Institutional Ownership Percentage: 59.12%
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/15/2016 | Amarpreet Sawhney | Insider | Buy | 45,300 | $7.85 | $355,605.00 | |
| 6/9/2016 | Amarpreet Sawhney | CEO | Buy | 10,000 | $6.70 | $67,000.00 | |
| 11/17/2015 | Amarpreet Sawhney | CEO | Buy | 10,000 | $8.25 | $82,500.00 | |
| 9/15/2015 | James Fortune | COO | Sell | 9,470 | $17.16 | $162,505.20 | |
| 9/14/2015 | Amarpreet Sawhney | CEO | Buy | 15,000 | $16.50 | $247,500.00 | |
| 6/15/2015 | Charles M Warden | Director | Sell | 320,000 | $22.00 | $7,040,000.00 | |
| 6/10/2015 | Charles M Warden | Director | Sell | 427,000 | $22.00 | $9,394,000.00 | |
| 6/10/2015 | Svlsf Iv, Llc | Major Shareholder | Sell | 1,119,000 | $22.00 | $24,618,000.00 | |
| 7/30/2014 | Amarpreet Sawhney | CEO | Buy | 76,922 | $13.00 | $999,986.00 | |
| 7/30/2014 | Svlsf Iv, Llc | Major Shareholder | Buy | 715,380 | $13.00 | $9,299,940.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ocular Therapeutix (NASDAQ:OCUL)
Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
| Source: |
|
| Date | Headline |
|---|
 | Analyzing Transenterix (TRXC) and Ocular Therapeutix (OCUL)
www.americanbankingnews.com - August 21 at 8:09 AM |
 | INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - August 19 at 6:09 AM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL
finance.yahoo.com - August 19 at 6:09 AM |
| DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 19 at 6:09 AM |
| APPROACHING DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 17 at 10:03 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL
finance.yahoo.com - August 17 at 5:01 PM |
| EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 17 at 5:01 PM |
| INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline - September 5, 2017
finance.yahoo.com - August 17 at 5:01 PM |
| The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)
finance.yahoo.com - August 17 at 5:01 PM |
| SHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 17 at 6:25 AM |
 | OCULAR THERAPEUTIX ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 ... - Business Wire (press release)
www.businesswire.com - August 16 at 6:28 AM |
| INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline - September 5, 2017
finance.yahoo.com - August 15 at 5:31 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
finance.yahoo.com - August 15 at 5:31 AM |
| UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 15 at 5:31 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL
finance.yahoo.com - August 12 at 6:33 AM |
| APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 12 at 6:32 AM |
| Edited Transcript of OCUL earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 12 at 6:32 AM |
| INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline - September 5, 2017
finance.yahoo.com - August 12 at 6:32 AM |
 | EQUITY ALERT UPDATE: Rosen Law Firm Announces Filing of Securities Class Action Against Ocular Therapeutix, Inc. - OCUL
feeds.benzinga.com - August 10 at 7:30 PM |
| INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline - September 5, 2017
finance.yahoo.com - August 10 at 6:26 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
finance.yahoo.com - August 10 at 6:26 AM |
| Ocular Therapeutix™ Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 6:26 AM |
| EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 10 at 6:26 AM |
| IMPORTANT OCULAR THERAPEUTIX, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Ocular Therapeutix, Inc.
finance.yahoo.com - August 10 at 6:26 AM |
| Ocular Therapeutix reports 2Q loss
finance.yahoo.com - August 10 at 6:26 AM |
| SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 10 at 6:26 AM |
| Ocular Therapeutix, Inc. (NASDAQ:OCUL) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - August 9 at 9:20 PM |
 | SHAREHOLDER ALERT: SFMS Announces Filing of Securities Class Action Lawsuit Against Ocular Therapeutix, Inc. - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:03 AM |
| Ocular Therapeutix™ Reports Second Quarter 2017 Financial Results and Provides Corporate Update - Business Wire (press release)
www.businesswire.com - August 9 at 6:03 AM |
| IMPORTANT OCULAR THERAPEUTIX, INC. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:03 AM |
| Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 8 at 7:46 AM |
| OCUL Investors Update: Hagens Berman Alerts Investors in Ocular Therapeutix, Inc. to Expanded Class Period in Pending Securities Class Action and Reminds Them of the September 5, 2017 Lead Plaintiff Deadline
finance.yahoo.com - August 8 at 3:32 AM |
| IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 8 at 3:32 AM |
| SHAREHOLDER ALERT: SFMS Announces Filing of Securities Class Action Lawsuit Against Ocular Therapeutix, Inc.
feeds.benzinga.com - August 7 at 10:25 AM |
| Ocular Therapeutix, Inc. (OCUL) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - August 6 at 10:02 AM |
| Ocular Therapeutix™ Appoints Daniel Bollag, Ph.D., as Senior Vice President, Regulatory Affairs, Pharmacovigilance ... - Business Wire (press release)
www.businesswire.com - August 5 at 5:15 AM |
| Ocular Therapeutix replaces regulatory chief after FDA rejection
finance.yahoo.com - August 5 at 5:15 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline – OCUL
finance.yahoo.com - August 5 at 5:15 AM |
| SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 5 at 5:15 AM |
| INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - August 4 at 6:34 AM |
| IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 4 at 6:34 AM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
finance.yahoo.com - August 4 at 6:34 AM |
| The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)
feeds.benzinga.com - August 2 at 10:56 AM |
 | BRIEF-Ocular Therapeutix to eliminate 26 positions across organization
www.reuters.com - August 2 at 6:32 AM |
| Safirstein Metcalf LLP Reminds Investors That A Class Action Has Been Filed Against Ocular Therapeutix, Inc. – OCUL
finance.yahoo.com - August 2 at 6:32 AM |
| Ocular Therapeutix™ Announces Antony Mattessich Assumes Role as Chief Executive Officer
finance.yahoo.com - August 2 at 6:32 AM |
| INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - August 2 at 6:32 AM |
| Bedford’s Ocular Therapeutix turns to layoffs after FDA rejection
finance.yahoo.com - August 2 at 6:32 AM |
| INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) & Lead Plaintiff Deadline: September 5, 2017
finance.yahoo.com - August 1 at 4:59 AM |
| Ocular Therapeutix™ to Report Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - July 31 at 11:55 PM |
Ocular Therapeutix (OCUL) Chart for Monday, August, 21, 2017
